In another Phase II study, TAS-120 demonstrated comparable anti-tumor activity in patients with advanced or metastatic gastric and gastroesophageal cancer harboring FGFR2 amplification, with median PFS and OS estimates of 2.8 months and 5.7 months [130]. The gene discussed is FGFR2; the disease is neoplasm.